(Total Views: 143)
Posted On: 07/12/2025 6:16:44 PM
Post# of 8485
Keith Nalepka and VLMS Global Healthcare could play a complementary role in amplifying the strategic potential of a BIEL–Viant partnership, especially if the goal is to bring a smartphone-connected AI health app to market. Here's how they might factor in:
Keith Nalepka: The Commercial Catalyst
Keith Nalepka, currently President of VLMS Global Healthcare, has a rich background in:
1) Sales and marketing leadership at BIEL
2) Retail distribution strategy across major chains like Walgreens, CVS, and Target
3) Board-level involvement with BIEL, suggesting ongoing influence on strategic direction
His strengths could be pivotal in:
1) Go-to-market execution for a connected ActiPatch or RecoveryRx device
2) Retail and channel partnerships to scale distribution
3) Investor and stakeholder engagement, especially if BIEL pursues aggressive growth or viral adoption strategies
VLMS Global Healthcare: Operational Amplifier
VLMS specializes in medical coding, revenue cycle management (RCM), and healthcare data services. While not directly involved in device manufacturing, VLMS could:
1) Support reimbursement strategy by helping BIEL navigate CMS coding once FDA clearance and CMS approval are secured
2) Enable backend infrastructure for clinical data capture, billing, and insurance integration
3) Facilitate partnerships with hospital systems or insurance networks for broader adoption
Note: VLMS cannot initiate CMS coding or reimbursement without prior approval for BIEL’s devices—but once approved, they could streamline the process.
Strategic Triangle: BIEL + Viant + VLMS
Role Contribution:
BIEL - Core technology (PEMF devices, FDA clearances)
Viant - Hardware, firmware, app development
VLMS - Commercialization, reimbursement, data services
Nalepka - Sales strategy, retail access, investor relations
Together, this trio could transform ActiPatch into a connected, reimbursable, and widely distributed health tech product—bridging innovation, infrastructure, and market reach.
Keith Nalepka: The Commercial Catalyst
Keith Nalepka, currently President of VLMS Global Healthcare, has a rich background in:
1) Sales and marketing leadership at BIEL
2) Retail distribution strategy across major chains like Walgreens, CVS, and Target
3) Board-level involvement with BIEL, suggesting ongoing influence on strategic direction
His strengths could be pivotal in:
1) Go-to-market execution for a connected ActiPatch or RecoveryRx device
2) Retail and channel partnerships to scale distribution
3) Investor and stakeholder engagement, especially if BIEL pursues aggressive growth or viral adoption strategies
VLMS Global Healthcare: Operational Amplifier
VLMS specializes in medical coding, revenue cycle management (RCM), and healthcare data services. While not directly involved in device manufacturing, VLMS could:
1) Support reimbursement strategy by helping BIEL navigate CMS coding once FDA clearance and CMS approval are secured
2) Enable backend infrastructure for clinical data capture, billing, and insurance integration
3) Facilitate partnerships with hospital systems or insurance networks for broader adoption
Note: VLMS cannot initiate CMS coding or reimbursement without prior approval for BIEL’s devices—but once approved, they could streamline the process.
Strategic Triangle: BIEL + Viant + VLMS
Role Contribution:
BIEL - Core technology (PEMF devices, FDA clearances)
Viant - Hardware, firmware, app development
VLMS - Commercialization, reimbursement, data services
Nalepka - Sales strategy, retail access, investor relations
Together, this trio could transform ActiPatch into a connected, reimbursable, and widely distributed health tech product—bridging innovation, infrastructure, and market reach.
(1)
(0)
